BioSante Pharmaceuticals, Inc. (BPAX)

[Just the facts maam]

I can't tell you where it will be but I can tell you that BPAX was floating around the $2.50 and the average analyst 1 yr target price was $6 prior to the December drop. Libigel was presumed dead by many.

Since then:

Bio-t-Gel strongly appears to be heading for PDUFA approval

But make no mistake Libigel the big prize (was never dead)and with the 2012 patent applications regarding Libigel outlining a 70% reduction in cardiovascular disease in addition to subset analysis of efficacy data, plus a 90% chance of not only meeting but exceeding safety trials in addition to the possibility that Libigel improves cognitive functioning. It looks like Libigel could very well be a much bigger product then originally realized. Female Viagra which will not only will help you live longer but can help delay the onset of alzhiemers. Even if the Female Viagra can arguably be matched by a placebo the health benefits are not there with the placebo.

Long term there is the cancer research.

In the end make your own assessment. But earlier I suggested that the any realistic buyout should be in the $1 billion ($9 to $10 per share) and that would have to come out before the safety results are made public later this summer . Afterwards the price will only go up. Those who have truly have researched BPAX know what I am talking about.